Lafont R, Dinan L
Université Pierre et Marie Curie, Institut de Biologie Intégrative, Laboratoire d'Endocrinologie Moléculaire et Evolution, 7 Quai Saint Bernard, Case Courrier No 29, 75252 Paris Cedex 05, France.
J Insect Sci. 2003;3:7. doi: 10.1093/jis/3.1.7.
Ecdysteroids are widely used as inducers for gene-switch systems based on insect ecdysteroid receptors and genes of interest placed under the control of ecdysteroid-response elements. We review here these systems, which are currently mainly used in vitro with cultured cells in order to analyse the role of a wide array of genes, but which are expected to represent the basis for future gene therapy strategies. Such developments raise several questions, which are addressed in detail. First, the metabolic fate of ecdysteroids in mammals, including humans, is only poorly known, and the rapid catabolism of ecdysteroids may impede their use as in vivo inducers. A second set of questions arose in fact much earlier with the pioneering "heterophylic" studies of Burdette in the early sixties on the pharmacological effects of ecdysteroids on mammals. These and subsequent studies showed a wide range of effects, most of them being beneficial for the organism (e.g. hypoglycaemic, hypocholesterolaemic, anabolic). These effects are reviewed and critically analysed, and some hypotheses are proposed to explain the putative mechanisms involved. All of these pharmacological effects have led to the development of a wide array of ecdysteroid-containing preparations, which are primarily used for their anabolic and/or "adaptogenic" properties on humans (or horses or dogs). In the same way, increasing numbers of patents have been deposited concerning various beneficial effects of ecdysteroids in many medical or cosmetic domains, which make ecdysteroids very attractive candidates for several practical uses. It may be questioned whether all these pharmacological actions are compatible with the development of ecdysteroid-inducible gene switches for gene therapy, and also if ecdysteroids should be classified among doping substances.
蜕皮甾体被广泛用作基于昆虫蜕皮甾体受体和置于蜕皮甾体反应元件控制下的目的基因的基因开关系统的诱导剂。我们在此回顾这些系统,它们目前主要用于体外培养细胞,以分析大量基因的作用,但有望成为未来基因治疗策略的基础。此类进展引发了几个问题,将详细探讨。首先,包括人类在内的哺乳动物中蜕皮甾体的代谢命运鲜为人知,蜕皮甾体的快速分解代谢可能会阻碍其作为体内诱导剂的使用。事实上,早在60年代初Burdette对蜕皮甾体对哺乳动物的药理作用进行开创性的“异种”研究时就出现了另一组问题。这些以及后续研究显示了广泛的作用,其中大多数对生物体有益(例如降血糖、降胆固醇、合成代谢)。对这些作用进行了综述和批判性分析,并提出了一些假设来解释其中涉及的假定机制。所有这些药理作用都导致了大量含蜕皮甾体制剂的开发,这些制剂主要因其对人类(或马或狗)的合成代谢和/或“适应原性”特性而被使用。同样,关于蜕皮甾体在许多医学或美容领域的各种有益作用,已提交了越来越多的专利,这使得蜕皮甾体成为几种实际用途非常有吸引力的候选物。这些药理作用是否都与用于基因治疗的蜕皮甾体诱导基因开关的开发兼容,以及蜕皮甾体是否应归类为兴奋剂,可能会受到质疑。